BioCentury

1:29 AM GMT, Oct 2, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

Additional OS details for T-DM1

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said T-DM1 led to median overall survival (OS) of 30.9 months vs. 25.1 months for Tykerb

Read the full 240 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.